iBio Reveals Pricing for $50 Million Public Offering

Public Offering Announcement: iBio, Inc. has priced an underwritten public offering of pre-funded warrants and Series G and H warrants to purchase shares of its common stock, aiming to raise approximately $50 million.

Warrant Details: The pre-funded warrants are immediately exercisable, while the Series G and H warrants have specific exercise prices and expiration conditions related to clinical trial milestones.

Use of Proceeds: iBio plans to use the proceeds from this offering to advance its preclinical cardiometabolic programs and other pipeline assets, as well as for general corporate purposes.

Forward-Looking Statements: The announcement includes forward-looking statements regarding iBio's future developments and potential risks that could affect the company's performance and offerings.